AstraZeneca Bets Long Term on Cancer Drugs

U.K.-listed drug maker AstraZeneca said its pipeline of drugs is expected to drive strong and consistent revenue growth, delivering annual revenues in excess of $45 billion by 2023.



from WSJ.com: US Business http://ift.tt/1u4JxWB

via IFTTT